Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 5, p. 307, doi. 10.1177/1758834017692779
- By:
- Publication type:
- Article
Works matching IS 17588340 AND DT 2017 AND VI 9 AND IP 5
Results: 5
1
2
Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 5, p. 319, doi. 10.1177/1758834017698644
- By:
- Publication type:
- Article
3
Cancer-induced muscle wasting: latest findings in prevention and treatment.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 5, p. 369, doi. 10.1177/1758834017698643
- By:
- Publication type:
- Article
4
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 5, p. 335, doi. 10.1177/1758834017693195
- By:
- Publication type:
- Article
5
History and current state of immunotherapy in glioma and brain metastasis.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 5, p. 347, doi. 10.1177/1758834017693750
- By:
- Publication type:
- Article